For Immediate Release

DiCE Molecules
Directed Evolution Meets Chemistry

DiCE Molecules Appoints Industry Veteran Richard Scheller to Board of Directors

SAN FRANCISCO, Calif. – May 11, 2016 – DiCE Molecules, a privately held company developing a next generation approach to small molecule drug discovery, today announced the appointment of Richard Scheller, Ph.D., chief scientific officer and head of therapeutics at 23andMe, to its board of directors. Dr. Scheller brings to DiCE nearly 20 years of leadership in drug discovery research and development.

"I have known Richard for years and had the opportunity to work with him early in my career at Genentech - he is truly a visionary and a distinguished leader in oncology, neuroscience, immunology and infectious disease drug development," said Kevin Judice, president and chief executive officer of DiCE. "I am delighted to have the opportunity to work with him again as a member of our board and we look forward his guidance and leadership as we further prove out our science and bring potential drug targets into the clinic."

About Dr. Scheller
Prior to 23andMe, Dr. Scheller spent 14 years at Genentech, where he served in various research and development roles until his retirement. Most recently, he was executive vice president of research and early development, focusing on the company's research strategy, drug discovery, business development and early drug development activities. From 1982 to 2001, Dr. Scheller served on the faculty of Stanford University as a professor in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center. In 2013, Dr. Scheller received the Albert Lasker Basic Medical Research Award for discoveries concerning the molecular machinery and regulatory mechanism that underlie the rapid release of neurotransmitters. Since 2004, Dr. Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Dr. Scheller has published more than 200 primary research papers during his career. Dr. Scheller holds a B.S. in biochemistry from the University of Wisconsin-Madison and a Ph.D. in chemistry from California Institute of Technology (Caltech).

"DiCE's unique Directed Chemical Evolution approach has significant potential to solve a long-standing issue in the drug development process that has plagued researchers for years—finding orally available drugs that can block protein-protein interfaces," said Dr. Scheller. "I am thrilled to partner with the team as they continue to grow and innovate."

About DiCE Molecules
DiCE Molecules is a privately held company focused on the development of small molecule compounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. Utilizing its unique approach, DiCE can amplify the strongest potential drug candidates and, by combining massive diversity with amplification and selection, substantially increase the probability of success.

For Immediate Release

In March 2016, Dice Molecules and Sanofi announced a five-year global collaboration to discover potential new therapeutics for up to 12 targets that encompass all disease areas of strategic interest to Sanofi. The collaboration builds upon DiCE's unique technology platform. The company is focused on leveraging its capabilities to create a self-financing business generating returns for its internal shareholders through the achievement of milestones and revenues secured www.dicemolecules.com.

###

Media Contact:
Katie Engleman
Pure Communications
919-333-7722
katie@purecommunicationsinc.com